Core Viewpoint - MIRXES-B (02629) has seen a significant increase in stock price, reaching a new high of 40.66 HKD, which is over 70% higher than its IPO price of 23.3 HKD [1] Company Overview - Mirxes is a Singapore-based RNA biotechnology company focused on developing and commercializing precise, non-invasive, and affordable blood miRNA tests for early cancer and other disease screening [1] - The flagship product, GASTROClear™/觅小卫™, is a blood miRNA-based molecular diagnostic kit for gastric cancer screening, approved in multiple countries including Singapore and the EU, and has received breakthrough medical device certification from the US FDA [1] - GASTROClear™ has completed a prospective clinical trial with a sample size of 9,472 in China and is currently in the registration application process [1] Market Position - According to Guoyuan International, the company holds significant technological, product, and market advantages in the field of miRNA-based early cancer detection, positioning it as a global leader [1] - Everbright Securities International noted the vast market potential for global cancer screening, highlighting high industry entry barriers [1] - GASTROClear™ is the only approved molecular diagnostic IVD product for gastric cancer screening globally, holding the largest market share of 66.3% in the Southeast Asian miRNA liquid biopsy gastric cancer screening market as of 2023 [1]

Core Insights - Mainz Biomed has received regulatory approval from Swissmedic for its non-invasive colorectal cancer screening test, ColoAlert, allowing it to be distributed in Switzerland [1][3][4] - The target demographic for colorectal cancer screening in Switzerland includes individuals aged 50 to 74, with an estimated population of 2.8 million in this age group, representing approximately 31.4% of the total population [2] - Current participation rates in existing screening programs are below 50%, indicating a significant opportunity for ColoAlert to enhance participation and support national health objectives [2][4] Company Overview - Mainz Biomed specializes in molecular genetics diagnostics, focusing on early cancer detection, with ColoAlert being its flagship product [5] - The company is expanding its market presence through partnerships with local laboratories and healthcare providers to ensure broad access to its diagnostic solutions [4][5] - In addition to ColoAlert, Mainz Biomed is developing PancAlert, an early-stage pancreatic cancer screening test [5]

Core Viewpoint - The statement from Aikang Group addresses a complaint from a client, Ms. Zhang, regarding the accuracy of her health check results over a ten-year period, highlighting the complexities of cancer detection and the limitations of current diagnostic methods [1] Group 1: Company Response - Aikang Group released a statement on July 17, responding to media reports about Ms. Zhang's cancer diagnosis after ten years of normal test results [1] - The company emphasizes that cancer development is a gradual process influenced by various factors, including the timing of tests, detection methods, and the expertise of medical professionals [1] - Aikang Group plans to collaborate with a third-party authority and experts to analyze the situation and will accept responsibility if found at fault [1] Group 2: Industry Context - According to the 2022 edition of the "Guidelines for Diagnosis and Treatment of Renal Cell Carcinoma" published by the People's Medical Publishing House, there are currently no recognized serum tumor markers for the early auxiliary diagnosis of renal cell carcinoma [2] - The cancer embryonic antigen (CEA) test mentioned by Ms. Zhang is not acknowledged as a reliable indicator for assessing the risk of renal cell carcinoma [2]

据港交所披露，上周（5月12日至5月18日）共有2家公司递表，3家通过聆讯，4家公司招股，1家公司上 市。 2家公司递表：东方妍美、诺比侃科技递表 1 ）东方妍美 ( 成都 ) 生物技术股份有限公司（简称 " 东方妍美 " ） 5月12日，东方妍美递表港交所，建银国际担任其独家保荐人。 据招股书介绍，东方妍美主要从事再生医学医疗器械及特医食品研发、生产及商业化。截至2025年5月5 日，公司拥有13款主要再生医学材料注射剂候选产品(均属第三类医疗器械)，包括核心产品XH301及用 于治疗女性压力性尿失禁的候选产品XH321，相关13款候选产品中的两款候选产品已进入注册审评阶 段。 经营业绩方面，2023年和2024年，东方妍美营业收入分别为人民币1288.2亿和1452.0亿元，同期净亏损 分别为人民币6350.1万和6938.3万元。 2 ）诺比侃人工智能科技 ( 成都 ) 股份有限公司（简称 " 诺比侃科技 " ） 5月14日，诺比侃科技递表港交所，中金公司担任其独家保荐人。 招股书显示，诺比侃科技专注于人工智能技术和数字孪生等先进技术，在AI+交通、AI+能源及AI+城 市治理等领域的产业化应用。公司主 ...

Core Insights - Mirxes Holding Company Limited (Mirxes Group) is nearing its IPO after a lengthy process involving four submissions, with the listing hearing successfully passed on May 12 [1] - The company specializes in RNA technology, focusing on early disease detection diagnostic solutions globally [1] - The largest shareholder is Sun Tongyu, a prominent figure in Alibaba, adding a layer of intrigue to the company's profile [1] Company Overview - Founded in 2014 by three PhDs, Mirxes Group has concentrated on developing cancer test kits since its inception [1] - The company is recognized as a provider of effective, non-invasive, and affordable blood-based miRNA test kits for early cancer and disease detection, according to Frost & Sullivan [1] Product Development - As of April 27, 2025, Mirxes Group has established a comprehensive product matrix, including one core product (GASTROClearTM), two commercialized products (LUNGClearTM and FortitudeTM), and six candidates in preclinical stages [2] - GASTROClearTM is particularly notable as it is the first and only approved molecular diagnostic IVD product for gastric cancer screening globally, having received certification from Singapore's Health Sciences Authority in May 2019 [3] Financial Performance - The company reported revenues of approximately $17.76 million, $24.19 million, and $20.28 million for the years 2022, 2023, and 2024, respectively, with corresponding gross profits of about $9.33 million, $13.58 million, and $8.89 million [3] - Losses for the same periods were approximately $56.20 million, $69.57 million, and $92.21 million [3] Investment and Valuation - Mirxes Group has attracted significant investment from various notable capital firms, including Gao Rong Capital and Nuo Hui Capital, with a post-investment valuation of $600 million following a Series D funding round in July 2023 [3][4] - The company’s major shareholders include Sun Tongyu (22.03%), Dr. Zhu Xingfen (14.11%), and Dr. Zhou Lihan (8.12%), among others [5] IPO Utilization - The primary use of funds raised from the IPO will be for the research and development, regulatory filing, and production of the core product GASTROClearTM, as well as funding ongoing and planned R&D projects [7] - The company aims to enhance and integrate its "end-to-end" capabilities through the raised capital [7] Future Outlook - With the successful passage of the listing hearing and strong backing from capital and technological innovation, Mirxes Group's future development appears promising in the early disease detection sector [8]